Melanoma Genetics: Recent Findings Take Us Beyond Well-Traveled Pathways  by Law, Matthew H. et al.
Melanoma Genetics: Recent Findings Take Us Beyond
Well-Traveled Pathways
Matthew H. Law1, Stuart MacGregor1 and Nicholas K. Hayward1
Genetic linkage and candidate gene studies have identified a number of genes involved in melanoma
susceptibility, such as MC1R and CDKN2A, via the endophenotypes of pigmentation and nevus proliferation. A
series of genome-wide association studies (GWASs) in 2008 and 2009 showed that a handful of additional genes
(e.g., ASIP, TYR, and PLA2G6) influencing these endophenotypes also affected melanoma risk. The most recent
wave of melanoma GWASs has uncovered genes functioning independently of the known melanoma-
associated phenotypes, highlighting the role of processes such as DNA repair and cell cycle control. We take
this opportunity to summarize these new and exciting findings and integrate them into the current framework
of our understanding of melanoma genetics.
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INTRODUCTION
Of the three most prevalent types of
skin cancer, melanoma is the most
deadly. Melanoma is the fourth most
commonly reported cancer in Australia,
with an age-standardized incident rate
of 46.7 per 100,000 (Australian Institute
of Health and Welfare (AIHW), 2010).
Although lower, rates elsewhere are still
concerning, with an age-adjusted in-
cidence rate of 18.7 per 100,000 in the
United States in 2007 (US Cancer
Statistics Working Group, 2010) and
11.3 per 100,000 in the European
Union in 2008 (Ferlay et al., 2010).
Melanoma’s high incidence and poor
treatment outcome makes understand-
ing its underlying pathology critical.
Twin studies estimate that 55% of
the variation in melanoma liability is
due to genetic effects (Shekar et al.,
2009), and familial melanoma repre-
sents approximately 10% of new cases
(Hayward, 2003). Familial melanomas
are associated with highly penetrant
germline mutations in cyclin-dependent
kinase (CDK) inhibitor 2A (CDKN2A,
MIM: 600160, 9p21.3), a gene that
codes for two different tumor suppres-
sors: p16INK4a and p14ARF (Goldstein
et al., 2007). CDKN2A mutations are
found in 10% of families with two cases
of melanoma, rising to 30–40% of
families with X3 cases of melanoma
(de Snoo and Hayward, 2005). Other
highly penetrant mutations occur in
CDK4 (MIM: 123829, 12q14.1) and
BRCA1-associated protein 1 (BAP1,
MIM: 603089, 3p21.1; Wiesner et al.,
2011). Although informative in at-risk-
families, these highly penetrant
variants are rare (Hayward, 2003; de
Snoo and Hayward, 2005) and are not
responsible for the majority of melano-
ma cases. Although the high heritability
of melanoma and low familial rate
seems counterintuitive, under a poly-
genic threshold model (Yang et al.,
2010) it is plausible that given
melanoma’s low incidence of
0.0057 (Australian Institute of Health
and Welfare, 2008) the majority of
cases would be sporadic rather than
familial if a large proportion of the risk
arises from common genetic variants
with low risk. Indeed, a growing body
of evidence supports the role of com-
mon genetic variation in melanoma
risk in combination with common
environmental factors.
UVR is a major environmental risk
factor for melanoma (Veierod et al.,
2010), with cutaneous melanin provid-
ing significant protection (Cui et al.,
2007). Epidemiological studies have
confirmed that melanoma is primarily
a condition of the pale skinned, and
incidence is higher again in those with
red compared with dark hair (Bataille
et al., 1996; Grulich et al., 1996). The
number of atypical nevi and, to a lesser
extent, total nevi count are separately
associated with vastly increased rates
of melanoma, and red-headed indivi-
duals are more likely to have atypical
nevi (Bataille et al., 1996; Grulich
et al., 1996). Pooled analysis of risk
phenotypes provide melanoma odds
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ratio (OR) estimates for red hair
(OR¼1.9), fair skin (OR¼ 1.7), high
common nevus counts (OR¼ 7.9), and
X1 atypical nevi (OR¼ 4.0; Chang
et al., 2009). These are extremely high
for a complex disease, and there is
clear evidence of a spectrum of risk
with melanoma odds decreasing as
pigmentation increases and nevus
count decreases.
As we will briefly summarize, such
strong-risk endophenotypes enabled
modestly sized candidate gene studies
to identify risk alleles in genes modify-
ing these same traits. However, such
modest sample sets may have hampered
the detection of genes acting outside of
these high OR endophenotypes, with
many candidate gene associations ex-
hibiting the common problem of poor
replication. The advent of the first wave
of melanoma genome-wide association
studies (GWASs) (Brown et al., 2008;
Bishop et al., 2009) confirmed which of
the previously reported candidate genes
were reliably associated with melanoma
predisposition without generating any
new candidates. The recent publication
of a second wave of melanoma GWASs
with denser single-nucleotide poly-
morphism (SNP) coverage and larger
sample sizes (Amos et al., 2011; Barrett
et al., 2011; Macgregor et al., 2011) has
contributed exciting evidence of asso-
ciation with genes in additional path-
ways, and we take this opportunity to
integrate these recent findings with the
current understanding of melanoma
genetics.
THE GENETICS OF MELANOMA RISK
PHENOTYPES: PIGMENTATION
As said, melanin is protective against
UVR DNA damage, and detection of
cutaneous DNA damage leads to in-
creased production of melanocyte-
stimulating hormone from the proopio-
melancortin gene (POMC, MIM:
176830; Figure 1, Section a). Melano-
cyte-stimulating hormone binding to
the melanocortin-1 receptor (MC1R,
MIM: 155555, 16q24.3) results in
the induction of microphthalmia-
associated transcription factor (MITF,
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Figure 1. Melanogenesis. (a) UVR-induced cutaneous DNA damage upregulates melanocyte-stimulating hormone (MSH) signaling, leading to the activation of
the trans-membrane MC1R (melanocortin-1 receptor) receptor of melanocytes. MC1R activation can be inhibited by agouti signalling protein (ASIP), reducing
melanogenesis and related processes. (b) Activated MC1R induces expression of MITF (microphthalmia-associated transcription factor) mRNA via G protein
signaling. (c) Synthesis of the transcription factor MITF and its transport to the nucleus upregulates a range of genes required for melanogenesis. (d) OCA2
(oculocutaneous albinism type 2) and SLC45A2 (solute carrier family 45 member 2) encode proteins required for correct packaging of melanin synthesis
enzymes such as tyrosinase (TYR) and tyrosinase-related protein 1 (TYRP1) into melanosomes. (e) Tyrosine is metabolized into melanin by TYR, TYRP1, and
downstream enzymes (not shown). (f) Mature melanosomes are distributed to neighboring keratinocytes to protect against further UVR damage.
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MIM: 156845, Figure 1, Section c;
Giles et al., 2011). MITF is a transcrip-
tion factor that regulates a suite of
genes involved in cell cycle control
and melanogenesis (Cheli et al., 2010).
These functions allow MITF to mediate
differentiation and survival of melano-
cytes while limiting their uncontrolled
progression. Germ-line loss of MITF
abolishes melanocyte formation in
mice, whereas its loss in estab-
lished melanocyte gives rise to their
expansion (Cheli et al., 2010). MITF
achieves this partly via inducing senes-
cence through expression of p16INK4a,
p21, and anti-apoptosis genes such as
B-cell lymphoma 2 (BCL2, MIM:
151430, 18q21.33) and apex nuclease
1 (APEX1, MIM: 107748, 14q11.2;
Cheli et al., 2010; Figures 2, 3).
Recently, two independent groups
identified a rare functional non-synon-
ymous SNP rs149617956 (E318K) in
MITF that alters MITF transcriptional
activity, and is associated with a large
population-wide melanoma risk esti-
mated between OR 2.19 (95% CI 1.41,
3.45; Yokoyama et al., 2011) and 4.78
(95% CI 2.05, 11.75; Bertolotto et al.,
2011). Bertolotto et al. (2011) observed
that rs149617956 also associates with a
higher incidence of renal cancer, likely
owing to an isoform of MITF that
regulates kidney development. E318K
is also associated with increased nevus
count and non-blue eye color, consis-
tent with its enhanced transcriptional
ability. Adjusting for these traits
reduced (OR 1.82, 95% CI 0.85, 3.92)
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Figure 2. Melanocyte proliferation and response to DNA damage. (a) Melanocyte proliferation is enhanced by a range of growth factors that activate mitogen-
activated protein kinase (MAPK) signaling with resultant stimulation of cyclin D1 (CCND1) and cyclin-dependent kinase 4 (CDK4) pathways. MAPK signaling
is enhanced by activation of v-raf murine sarcoma viral oncogene homolog B1 (BRAF). (b) Activation of CCND1/CDK4 increases proliferation, whereas their
repression induces senescence and can eventually lead to apoptosis. (c) UVR interacting with cells is either absorbed by melanin, generates reactive oxygen species
(ROS) through collisions with cell lipids or proteins, or directly impacts DNA. (d) DNA damage can result directly from UVR absorption, with a range of results
depending on photon energy, or indirectly through ROS mediated oxidation of DNA bases. Specific mechanisms of DNA damage detection and repair are detailed
in Figure 3. (e) In response to DNA damage, the master cell cycle regulator p53 is phosphorylated (p), activating its transcription factor ability. The resulting
increased expression of the CCND1 inhibitor p21 blocks cell cycle progression. (f) Detection of DNA damage also upregulates melanogenesis via melanocyte-
stimulating hormone signaling to protect against further damage (see Figure 1). Microphthalmia-associated transcription factor (MITF) increases transcription of the
two alternative products of CDKN2A (CDK inhibitor 2A), p16INKA and p14ARF. p16INKA inhibits CDK4, blocking cell cycle progression, whereas p14ARF upregulates
p53. (g) A range of other factors can interact with this process, such as micro-RNA (miR) 193b, which can inhibit CCND1. MDM2, mouse double minute 2.
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but did not abolish E318K association
with melanoma (Yokoyama et al.,
2011).
Thus, there is a positive feedback
loop in melanocytes; UVR damage
increases melanin production and
blocks cell cycle progression via MITF
until DNA damage is no longer de-
tected (Figures 2 and 3). In turn, an
individual’s ability to activate the
MC1R pathway will influence both
pigmentation and their risk of melano-
ma. Indeed, human coloration is
strongly influenced by variation in the
highly polymorphic MC1R gene. A
number of rare recessive MC1R alleles
are highly penetrant for red hair and
poor UVR-induced tanning response.
Each allele exhibits little linkage dis-
equilibrium (LD) with one another, and
the majority of individuals with red hair
are compound heterozygotes (Duffy
et al., 2010). These alleles are usually
pooled as ‘‘red hair color’’ alleles for
study, and meta-analysis indicates that
red hair color alleles are associated
with melanoma (OR 1.4–2.4) in propor-
tion to their red hair penetrance (Rai-
mondi et al., 2008).
Given its protective nature, melano-
ma researchers have expended signifi-
cant effort testing skin coloration genes
derived from animal studies, identified
as targets of MITF (Figure 1), or high-
lighted by human pigmentation
GWASs (Sulem et al., 2007; Han
et al., 2008). As is often the case with
such studies, these have been plagued
by inconsistent replication. Some genes
achieved strong support, including the
MITF-regulated solute carrier family 45
member 2 gene (SLC45A2, MIM:
606202, 5p13.2; Fernandez et al.,
2008; Guedj et al., 2008), and the
oculocutaneous albinism type 2 gene
(OCA2, MIM: 611409, 15q12-q13;
Jannot et al., 2005; Guedj et al.,
2008; Nan et al., 2009; Figure 1,
Section d). While a SNP in the region
untranslated region of the gene encod-
ing agouti signalling protein (ASIP,
MIM: 600201, 20q11.22, Figure 1,
Section a) was associated with pigmen-
tation traits but not melanoma (Kanets-
ky et al., 2002; Meziani et al., 2005),
larger GWAS-based approaches con-
firmed haplotypes near ASIP were asso-
ciated with melanoma (Brown et al.,
2008; Gudbjartsson et al., 2008;
Bishop et al., 2009; Nan et al., 2009).
Similarly, a missense SNP (rs1126809)
in the tyrosinase gene (TYR, MIM:
606933, 11q14.3) and a promoter
SNP (rs1408799) in the gene for tyros-
inase-related protein 1 (TYRP1, MIM:
115501, 9p23), both of which encode
melanogenesis enzymes (Sturm et al.,
1995; Figure 1, Section e), have been
sporadically associated with melanoma
(Gudbjartsson et al., 2008; Nan et al.,
2009). The retention of increased risk
for melanoma from known melanogen-
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Figure 3. DNA damage detection and repair. (a) UVR can damage DNA in a number of ways (Figure 2), and specific repair systems address the different types of
damage. (b) Damage to individual or small numbers of bases, such as resulting from reactive oxygen species (ROS) oxidation, is repaired by the base excision
repair system, of which poly(ADP-ribose) polymerase 1 (PARP1) is an integral component. Apex nuclease 1 (APEX1), although only weakly associated with
melanoma, is of interest as it can activate p53 in an ataxia–telangiectasia-mutated (ATM)–independent manner. (c) Large UVR-induced DNA lesions are detected
by ATM, leading to p53 activation and lesion repair by nucleotide excision repair (NER). Constitutive loss of any NER component leads to xeroderma pigmentosa
(XP), a disease associated with a high incidence of melanoma. Here, any member of this protein complex has been indicated by the common label ‘XP’. (d) UVR
can erode telomeres, a process opposed by the telomere maintenance enzyme telomerase reverse transcriptase (TERT). Functional and intact telomeres block
ATM recognition of chromosome ends as a double-strand DNA break, whereas exposed chromosome ends activates ATM, again leading to p53-mediated cell
cycle blockage. MDM2, mouse double minute 2.
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esis genes even when pigmentation is
accounted for (Guedj et al., 2008;
Raimondi et al., 2008; Table 1) sug-
gests that either their involvement
in melanoma is mediated through addi-
tional pathways or incomplete adjust-
ment for confounding effects (Gerstenblith
et al., 2010).
THE GENETICS OF MELANOMA RISK
PHENOTYPES: NEVUS COUNT
The role of MITF in regulating cell
senescence, as well as melanin produc-
tion, indicates that response to UVR
damage requires controlled melanocyte
proliferation and not just distribution of
cutaneous melanosomes. Indeed, over-
expression of oncogenes such as v-raf
murine sarcoma viral oncogene homo-
log B1 (BRAF, MIM: 164757, 7q34;
Figure 2) induces a limited expansion
of melanocyte numbers, forming benign
nevi. Contrary to pigmentation, before
the publication of a GWAS for nevus
count (Falchi et al., 2009), little was
known about the genetics of this
melanoma endophenotype, although
linkage analysis suggested a role for
CDKN2A (Falchi et al., 2006; Zhu et al.,
2007). The GWAS of Falchi et al., 2009
confirmed that nevus number associates
with common variation in 9p21.3,
spanning the methylthioadenosine
phosphorylase (MTAP, MIM: 15640)
and CDKN2A loci. The most replicated
melanoma SNPs fall in one LD block
spanning the promoter and 50 end of the
MTAP gene (Figure 4, LD block 1).
There is an additional SNP (rs3088440;
Figure 4) that falls in a second LD block
spanning the CDKN2A gene, although
the association with rs3088440 is ques-
tionable because of violations of the
Hardy–Weinberg equilibrium in con-
trols (Chatzinasiou et al., 2011).
Recent GWASs of type 2 diabetes
and coronary artery disease have
reported hits from SNPs in block 2
(Figure 4), which extends into an
adjacent intergenic desert (block 3,
Figure 4). Detailed functional analysis
of this region has shed light on the
complex regulatory structures in this
region, and indicates that blocks 2 and
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Figure 4. Linkage disequilibrium plot of the 9p21.3 locus. The image uses reported single-nucleotide polymorphisms (SNPs) available in haplotype map
release 2, with linkage disequilibrium (LD) visualized as D0 via the Haploview program (Barrett et al., 2005). SNPs are highlighted relative to the source
publication reporting their melanoma association (Bishop et al., 2009; Chatzinasiou et al., 2011). Type 2 diabetes–and coronary artery disease (CAD)–associated
SNPs are taken from Harismendy et al. (2011). The top CAD SNP (rs10757278) discussed in Harismendy et al. (2011), although not in the plot, is in high LD
(r240.85) with SNPs in blocks 2 and 3.
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3 are highly and significantly enriched
for enhancer sequences that regulate
the expression ofMTAP, CDKN2A, and
other genes in this region (Harismendy
et al., 2011). This observation is of
general interest given the number of
gene deserts identified by GWASs to be
associated with various traits. Given
the high LD between the melanoma-
associated rs3088440 and blocks 2/3, it
is plausible to suggest that this same
enhancer function underlies the mela-
noma association. Unfortunately, LD
block 1 spanning MTAP, and which
represents the most reproducible mel-
anoma association, was not studied by
Harismendy et al, (2011).
Falchi et al. (2009) and Duffy et al.
(2010) further identified the phospholi-
pase A2, group VI (PLA2G6, MIM:
603604, 22q13.1), and IFN regulatory
factor 4 (IRF4, MIM: 601900, 6p25.3)
genes as modifiers of nevus prolifera-
tion, respectively. PLA2G6 and IRF4
have also been shown to associate with
melanoma risk (Falchi et al., 2009;
Duffy et al., 2010; Kvaskoff et al.,
2011). However, whereas adjusting
for nevus count abolishes IRF4 and
PLA2G6 associations with melanoma
(Kvaskoff et al., 2011), MTAP associa-
tions were only slightly reduced (Bishop
et al., 2009; Falchi et al., 2009; Kvaskoff
et al., 2011), although as cautioned
previously this may reflect incomplete
control of confounds rather than multi-
ple roles in melanoma (Gerstenblith
et al., 2010). It seems likely that in
contrast to pigmentation, where the
bulk of population-wide variation
arises from relatively few high-impact
genes, the stronger melanoma risk trait
of nevus count emerges from a larger
pool of genes of smaller effect.
THE CURRENT STATE OF
MELANOMA GENETICS
In writing this review we owe a debt to
the recent and excellent systematic
meta-analysis of melanoma genetic
studies by Chatzinasiou et al, (2011).
Consolidating the extensive research
into melanoma genetics we have only
briefly discussed here, they highlighted
eight loci strongly supported as being
involved in melanoma susceptibility.
Six of these loci achieved the highest
grade of evidence. Five of these asso-
ciations represented genes involved in
melanin production: MC1R, TYR,
TYRP1, SLC45A2, and ASIP (summa-
rized in Table 1), although the locus
containing ASIP is very broad and the
signal may represent multiple genes
(Chatzinasiou et al., 2011). They also
confirm that the sixth high-quality
locus at 9p21.3 may represent two
signals, one fromMTAP and the second
from CDKN2A, each independently
associated with melanoma via nevus
formation. The two remaining loci
achieved lower quality scores as their
low ORs suggests that they are poten-
tially false positives arising from study
biases, yet are intriguing as they are
the first to point to pathways outside of
the canonical melanoma pathways of
pigmentation and nevogenesis. One
of these loci, at chromosome band
12q13.11, contains the vitamin D
receptor gene (VDR, MIM: 12q13.11).
The final locus, at 5p15.33, contains
telomerase reverse transcriptase (TERT,
MIM: 187270), which, as we will
discuss later, is likely involved in both
melanoma and nevus count.
THE NEXT GENERATION OF GWASs
PROVIDES NEW INSIGHTS INTO
MELANOMA GENETICS
We now review three recent GWASs
into melanoma, which used collections
from the American M.D. Anderson
Cancer Center (Amos et al., 2011), the
International Melanoma Genetics Con-
sortium (GenoMEL; (Barrett et al., 2011)),
and the report of Macgregor et al.,
(2011), which represents the combined
Queensland study of Melanoma: Envir-
onment and Genetic Associations
(Q-MEGA; Baxter et al., 2008) and the
Australian Melanoma Family Study
(Cust et al., 2009; AMFS). Each study
reported their most significant loci,
with independent in silico replication
conducted across studies. We will
briefly summarize the top hits for each
study (Table 1) before going on to
discuss their implications for our under-
standing of melanoma. Six of the eight
previously identified melanoma loci
(Chatzinasiou et al., 2011), MC1R,
CDKN2A/MTAP, TYR, ASIP, TERT,
and SLC45A2 reached genome-wide
significance in the individual or com-
bined GWASs (Table 1). For the
remaining two loci in the Q-MEGA/
AMFS data sets SNPs in TYRP1 and
VDR, although not genome-wide sig-
nificant, were at least nominally repli-
cated, with P values o5103
(Q-MEGA/AMFS, unpublished data).
This comprehensive replication of dec-
ades of candidate gene studies supports
the utility of sufficiently large popula-
tions to unambiguously identify risk
loci in an unbiased and genome-wide
manner. Importantly, it foreshadows
the power of GWAS to identify loci
that are not candidate genes or in
candidate pathways.
Utilizing M.D. Anderson Cancer
Center’s collection of 1,804 cases and
1,026 controls Amos et al., (2011)
detected genome-wide significant mel-
anoma associations with SNPs inMC1R
and a locus at 15p13.1 containing the
hect domain and RCC1-like domain 2
gene (HERC2, MIM: 605837, 15q13.1)
and OCA2, confirming previous asso-
ciations between 15p13.1 and pigmen-
tation and melanoma (Sturm et al.,
2008; Duffy et al., 2010). Amos et al.,
(2011) report that conditioning on the
top HERC2 SNP (rs12913832) removed
any residual association with OCA2
SNPs and suggest that the association
signal is localized to HERC2. However,
Sturm et al., (2008) indicate that
rs12913832 disrupts an evolutionarily
conserved helicase-like transcription
factor binding site sequence, and to-
gether with adjacent MITF-binding sites
suggests that the region is likely a cis
regulator of OCA2. Depending on the
population, rs12913832 explains be-
tween half and essentially all variation
in blue versus brown eye color (Sturm
et al., 2008; Amos et al., 2011). As
observed elsewhere, pigmentation dif-
ferences may arise simply from cryptic
study population substructure; control-
ling for European ancestry had essen-
tially no impact on rs12913832
associations (Amos et al., 2011). However,
rs12913832 or other SNPs in the
HERC2/OCA2 region evidenced non-
significant weak and heterogeneous
associations in the GenoMEL or Q-
MEGA/AMFS studies, suggesting that
the results for rs12913832 may be false
positive.
Following the initial GenoMEL study
(Bishop et al., 2009), Barrett et al.,
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(2011) report on a high-density GWAS
conducted on an expanded GenoMEL
sample of 2981 cases and 8408 con-
trols. In addition to known melanoma
genes, in silico combination of Geno-
MEL with the M.D. Anderson Cancer
Center and Q-MEGA/AMFS data sets
identified a further three loci at gen-
ome-wide significance levels. The most
Table 1. Melanoma-associated genetic variants
Location
Potential
gene
Genome-
wide
significant
MelGene
score MelGene OR Top SNPs GWAS OR Pigmentation Nevus
Independent
association
with
melanoma References
1q42 PARP1 Yes NA NA rs3219090 0.89 Weak Weak Yes Macgregor et al., 2011; Zhang
et al., 2011
1q21 Multitude Yes NA NA rs7412746 0.90 No No Yes Macgregor et al., 2011
2q33.1 CASP8 Yes NA NA rs13016963 1.14 (1.09,
1.19)
No Weak Yes Barrett et al., 2011
5p13.3-
13.2
SLC45A2 Yes A 0.4 (0.33, 0.47) rs16891982 0.36 (0.23,
0.53)
Yes No No Barrett et al., 2011; Guedj et al.,
2008; Fernandez et al., 2008;
Chatzinasiou et al., 2011
5p15.33 TERT Yes B 0.87 (1.15,
1.22)
rs401681 0.87 (0.81,
0.94)
No Weak Yes Law et al., 2011; Barrett et al.,
2011
9p21.3 CDKN2A Yes C, HWE
violated
1.25 (1.03,
1.51)
Multiple 0.83 (0.78,
0.88)
No Weak Yes See MTAP
9p21.3 MTAP Yes A B0.81 to
B0.84
Multiple As above No Weak Yes Bishop et al., 2009; Falchi et al.,
2009; Barrett et al., 2011;
Chatzinasiou et al., 2011
9p23 TYRP1 No A 0.86 (0.80,
0.93)
rs1408799 Not GW sig. Yes No No Gudbjartsson et al., 2008; Nan
et al., 2009; Chatzinasiou et al.,
2011
11q14.3 TYR Yes A 1.22 (1.14,
1.31)
rs1126809,
rs1393350
1.30 (1.21,
1.39)
Yes No No Gudbjartsson et al., 2008;
Bishop et al., 2009; Nan et al.,
2009; Chatzinasiou et al., 2011
11q22.3 ATM Yes NA NA rs1801516 0.84 (0.79,
0.89)
No No Yes Barrett et al., 2011
11q13.3 CCND1 No NA NA rs1485993 1.11 (1.04,
1.18)
No No Yes Barrett et al., 2011
12q13.11 VDR No C, OR
o1.15
0.89 (0.82,
0.97)
rs1544410 Not GW sig. No No Yes Chatzinasiou et al., 2011
15q13.1 OCA2 No NA NR rs12913832 Not GW sig. Yes No No Jannot et al., 2005; Guedj et al.,
2008; Fernandez et al., 2008;
Amos et al., 2011
16q24.3 MC1R Yes A 1.83 (1.56,
2.15)
rs1805007 1.70 (1.54,
1.87)
Yes No Yes Raimondi et al., 2008; Bishop
et al., 2009; Chatzinasiou et al.,
2011
20q11.22 ASIP Yes A 1.59 (1.41,
1.79)
Multiple From B1.20 to
B1.29
Yes No No Gudbjartsson et al., 2008;
Kanetsky et al., 2002; Meziani
et al., 2005; Bishop et al., 2009;
Nan et al., 2009; Chatzinasiou
et al., 2011
21q22.3 MX2 Yes NA NA rs45430 0.88 (0.85,
0.92)
No No Yes Barrett et al., 2011
22q13.1 PLA2G6 No NA 0.85 (0.79,
0.91)
rs6001027 0.85 (0.79,
0.91)
No Yes No Falchi et al., 2009; Duffy et al.,
2010; Barrett et al., 2011
Abbreviations: ASIP, agouti signaling protein; ATM, ataxia–telangiectasia mutated; CASP8, caspase 8; CCND1, cyclin D1; CDKN2A, cyclin-dependent
kinase inhibitor 2A; GWAS, genome-wide association study; HWE, Hardy–Weinberg equilibrium; MC1R, melanocortin-1-receptor; MTAP, methylthioa-
denosine phosphorylase; MX2, homologs of myxovirus resistance 2; NA, not applicable; OCA2, oculocutaneous albinism type 2; OR, odds ratio; PARP1,
poly (ADP-ribose) polymerase 1; PLA2G6, phospholipase A2, group VI; sig., significant; SLC45A2, solute carrier family 45 member 2; SNP, single-nucleotide
polymorphism; TERT, telomerase reverse transcriptase; TYR, tyrosinase; TYRP1, TYR-related protein 1; VDR, vitamin D receptor.
MelGene refers to the systematic review of Chatzinasiou et al. (2011), where the indicated quality scores and ORs were sourced from. Scores of A, B, and C
refer to strong, moderate, and weak epidemiological evidence, respectively, as assessed by Chatzinasiou et al. (2011). Where a single candidate gene or
associated SNP has been reliably associated at genome-wide significance levels, this has been indicated. Where available the equivalent ORs from GWASs
have been supplied for comparison with the systematic review ORs. If the likely mode of melanoma pathogenesis is via pigmentation, nevus proliferation, or
others, this has been indicated.
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likely genes based on SNP position and
local association signals are the poorly
characterized homologs of myxovirus
resistance 2 (MX2, MIM: 147890,
21q22.3), the apoptosis-related caspase
8 gene (CASP8, MIM: 601763), which
has been previously associated with a
range of cancers, including melanoma
in a single study (Yin et al., 2010), and
the ataxia–telangiectasia-mutated gene
(ATM, MIM: 607585, 11q22.3). Testing
a range of ATM SNPs in a small
case–control study detected a nonsigni-
ficant (OR 0.71, 95% CI 0.47, 1.07)
association with rs1801516 (Zhang
et al., 2011), which is in the same
direction as that reported by Barrett
et al., (2011). A locus containing the
proto-oncogene cyclin D1 (CCND1,
MIM: 168461, 11q13.3), which en-
codes a critical cell cycle regulatory
component with often elevated expres-
sion levels in melanoma (Chen et al.,
2010; Figure 2), did not quite reach
genome-wide significance in the com-
bined sample but likely represents a
valid melanoma risk gene.
Building on an earlier study (Brown
et al., 2008), we recently completed a
GWAS on the combined Q-MEGA/
AMFS sample of 2,168 cases and
4,387 controls (Macgregor et al.,
2011). This provided evidence for
two regions on chromosome 1, which
were independently replicated in sili-
co in the GenoMEL and M.D. Ander-
son Cancer Center data sets. The loci
are 75Mb apart and map to chromo-
somal bands 1q21.3 and 1q42, respec-
tively. The top hit for 1q21.3
(rs7412746) falls in a broad LD block
spanning multiple genes, with the
nearest genes being aryl hydrocarbon
receptor nuclear translocator (ARNT,
MIM: 126110) and the lysine 9–speci-
fic histone melthyltransferase SETDB1
(MIM: 604396). The only gene under-
lying the association signal in 1q42
is poly (ADP-Ribose) polymerase 1
(PARP1, MIM: 173870), with the
strongest association with a PARP1
promoter SNP (rs3219090). A com-
mon SNP (rs3219125) in PARP1 has
previously been associated with in-
creased melanoma risk (OR 3.13, 95%
CI 1.75,5.74) in a modest study (Zhang
et al., 2011), with the association
highest in head or neck melanoma,
suggesting a role in response to UVR
exposure.
BEYOND PIGMENTATION AND
NEVUS PROLIFERATION: DNA
DAMAGE REPAIR
Considering just the new hits (Table 1),
only SNPs in PARP1 or TERT were
weakly associated with pigmentation
or nevus count, respectively, and the
association of either loci with melano-
ma is not meaningfully changed by
controlling for these phenotypes (Law
et al., 2011; Macgregor et al., 2011).
The SNPs in 1q21.3 (Macgregor et al.,
2011) and ATM, CASP8, MX2, or
CCND1 (Barrett et al., 2011) were not
associated with these traits at all. That
is, it is highly likely that these studies
have identified genes for melanoma
outside of the two best-characterized
risk phenotypes. Considered together,
these genes highlight the role of DNA
damage repair in melanoma and iden-
tify links between DNA repair and
previously identified melanoma candi-
date genes. DNA damage repair is an
intuitive risk pathway for melanoma
given the importance of UVR exposure
in melanoma development, yet up until
now the only DNA repair gene reliably
associated has been TERT.
Assuming that they evade intercep-
tion by melanin (Figure 3), UVR
photons can damage DNA in a number
of ways depending on their energy
level. Lower-energy photons directly
impacting the DNA can generate pyr-
imidine (T or C) dimers, which are
detected and repaired by nucleotide
excision repair (NER; Marrot and Meu-
nier, 2008); it is the detection of these
pyrimidine dimers that upregulates
melanocyte-stimulating hormone, lead-
ing to melanogenesis (Figures 1, 3).
Highlighting the importance of NER in
melanoma is the vastly increased in-
cidence of melanoma in an autosomal
recessive syndrome, xeroderma pig-
mentosa, resulting from loss of function
in any of the groups of NER genes (Di
Lucca et al., 2009). Activation of NER
in turn induces ATM (Figure 3), a gene
that is intrinsically involved in DNA
repair. Higher-energy UVR photons
can induce dsDNA breaks, which are
repaired by NER, or indirectly damage
DNA by generation of reactive oxygen
species (Marrot and Meunier, 2008).
Oxidized DNA bases are replaced by
base excision repair (BER), of which
PARP1 is an integral component
(Figure 3). PARP1 is overexpressed in
a range of cancers, including melano-
ma (Ossovskaya et al., 2010). An
additional BER gene APEX1 has been
associated with an increase in melano-
ma risk in a single small study (Li et al.,
2006a). Although not replicated by
GWAS, apex nuclease 1 is of interest
as it links the BER system to p53
regulation independently of ATM (Tell
et al., 2005; Figure 3).
As shown in Figure 3, ATM is a
central figure in radiation-induced
DNA damage repair. Among a range
of effects, it activates the CDKN2A
product p14ARF, starting a cascade that
leads to cell cycle blockage by p53,
ensuring that cells stay in G1 until
damage is repaired by additional ATM-
regulated pathways (Derheimer and
Kastan, 2010). Alternatively ATM in-
duces senescence or apoptosis if levels
of damage are too severe (Marrot and
Meunier, 2008). p53 blockage of cell
cycle acts via CCND1 (Figure 2), an-
other candidate gene identified in the
recent GWASs. Cultured fibroblasts
lacking ATM expression are sensitive
to radiation induced death, a vulner-
ability that is rescued by ectopic
expression of ATM. Ectopic ATM in-
duces altered expression of a range of
cell cycle and apoptosis genes includ-
ing reduced expression of MCL1, a
gene found at the 1q21.1 melanoma-
associated locus (Table 1; Jung et al.,
2011). However, although ATM ex-
pression is increased in nevi and
melanoma, inhibition of ATM function
does not impair cultured melanoma
proliferation or increase radiotherapy-
or chemotherapy-induced cell death,
suggesting that there are additional
pathways (e.g., BER) in melanoma that
provides resistance to DNA damage
(Moschos et al., 2009). Although un-
common (o¼ 2.5% of the population),
heterozygosity for a deleterious non-
synonymous SNP (rs1800054) that al-
ters ATM binding to p53 is strongly
associated with melanoma (OR 2.3,
95% CI, 1.1, 5.0) (Dombernowsky
et al., 2008). Given the very different
frequencies of rs1800054 and the
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GWAS-associated SNPs, they likely
represent different association signals.
In addition to damaging coding
regions, UVR can lead to erosion of
telomeric DNA (Kruk et al., 1995).
Linear chromosomes, by definition,
end in unpaired DNA, and telomeres
act to block ATM recognition of these
ends as damaged DNA (Derheimer and
Kastan, 2010), and loss of telomeres
through normal cell division or damage
leads to ATM-induced senescence
(Herbig et al., 2004). Ataxia–telangiec-
tasia patients frequently exhibit chro-
mosome end-to-end fusion and other
telomere abnormalities, suggesting that
ATM also is required to maintain
telomeres, not merely respond to their
loss. Telomere maintenance by TERT
can delay senescence, which likely
explains why telomere length has been
positively associated with nevus count
(Bataille et al., 2007; Han et al., 2009).
The C allele of rs401681, a SNP near
TERT, is associated with increased odds
of a wide variety of cancers but appears
to be protective for melanoma in most
(Rafnar et al., 2009; Stacey et al., 2009;
Nan et al., 2011), although not all,
studies (Pooley et al., 2010). Similarly,
the finding that the rs401681 C allele
was associated with reduced telomere
length in one study (Nan et al., 2011)
was not observed in another study
(Pooley et al., 2010). Loss of CDKN2A
function combined with increased
TERT activity allows nevocytes to over-
come senescence and immortalize,
converting them into melanoma cells
(Ha et al., 2008), probably because
ATM can no longer lead to cell cycle
blockage via p14ARF.
We recently combined our results
for the TERT rs401681 SNP from the Q-
MEGA/AMFS data set with previously
published studies in a meta-analysis
(C allele random effects OR 0.873,
95% CI 0.812, 0.939; Law et al., 2011).
Although also associated with nevus
count, the melanoma association re-
mains after controlling for this endo-
phenotype (Law et al., 2011), an
observation confirmed by Barrett
et al., (2011). It is likely that the
rs401681C allele associates with these
traits by marking a low-function TERT
allele that makes melanocytes more
sensitive to ATM/p53-mediated senes-
cence. That rs401681C associates with
melanoma protection as opposed to the
increase in risk observed for other
cancer types may arise from additional
melanocyte specific pathways of cell
cycle control, such as MITF, counter-
acting the oncogenic impacts of telo-
mere ablation. It is interesting to
consider synergistic interactions be-
tween TERT and ATM alleles in such
processes, although this has not yet
been formally examined.
1q21.3: A WEALTH OF
CANDIDATES
There is a surfeit of strong candidate
genes in the 1q21.3 region in addition
to ARNT and SETDB1, including the
anti-apoptotic MCL1 (MIM: 159552),
and the cathespin-K gene (CTSK, MIM:
601105). CTSK encodes an extracellu-
lar protease regulated by MITF in
osteoblasts (Cheli et al., 2010), which
is implicated in assisting metastasis of
cancer cells (Zhao et al., 2009). ARNT
is a multifunction protein that trans-
ports a range of activated receptors to
the nucleus, where it is a partner in the
transcriptional response to hypoxia and
metabolism of xenobiotics. In addition
to directly generating carcinogenic
compounds via xenobiotic meta-
bolism, overactivation of ARNT by
2,3,7,8-tetrachlorodibenzo-p-dioxin
may assist melanoma metastasis
through inducing expression of matrix
metalloproteinases (Villano et al.,
2006), as well as inducing proliferation
by upregulating the p53 suppressor
mouse double minute 2 (MDM2,
MIM: 164785; Gim et al., 2010;
Figure 3). The broad association signal
observed for 1q21.3, combined with
high regional LD in humans makes fine
mapping difficult. However recent
work in zebra fish has provided evi-
dence for which of the 1q21.3 genes
may be responsible for the association
signal. Part of 1q21.3 is somatically
amplified in melanoma (Ceol et al.,
2011). Of the genes in the frequently
amplified region, only SETDB1 signifi-
cantly enhances melanoma develop-
ment in a zebrafish line carrying a
mutation homologous to the common
pro-melanoma-associated somatic
BRAF mutation seen in human mela-
noma (Ceol et al., 2011). SETDB1 is
overexpressed in a number of lung
cancer cell lines, and siRNA suppres-
sion of SETDB1 reduced anchorage-
independent colony growth without
altering adherent cell culture expan-
sion or apoptosis (Watanabe et al.,
2008). SETDB1 functionally associates
with the DNA methyl transferase
DNMT3A to silence the tumor-suppres-
sor gene RASSF1A (Li et al., 2006b).
POTENTIAL PATHWAYS TO
TREATMENT
Invasive melanoma has a particularly
poor prognosis and exhibits treatment
resistance. A number of the new
melanoma genes (Table 1) appear to
have a role in this resistance. As
mentioned above, ATM regulates repair
of large DNA lesions and double-strand
breaks (NER), whereas other genes,
including APEX1 and PARP1, regulate
smaller lesions via BER. Blocking of
BER through PARP1 inhibitors leaves
these aberrations unrepaired. Uncor-
rected small lesions eventually develop
into larger lesions detectable by the
NER machinery. In cancer cells lacking
NER response, BER inhibitors allow
selective lethality (Weston et al.,
2010). It is plausible that SNPs that
alter PARP1 and ATM could function
synergistically to increase DNA da-
mage, predisposing individuals to can-
cer, or increase resistance to anticancer
treatments and, in turn, variation in
CCND1, CDKN2A, and TERT could
interact both positively and negatively
in melanoma risk by altering propensity
for melanocytes to undergo senescence
in response to DNA damage. Further,
although Ceol et al., (2011) did not
detect MCL1 overexpression in mela-
noma cell lines carrying duplications of
1q21, a range of studies have reported
increased MCL1 expression in melano-
ma, where it may provide resistance to
an anticancer B-cell lymphoma family
inhibitor ABT-737. Inhibition of MCL1
expression enhances ABT-737-induced
apoptosis in melanoma in a CASP8-
dependent manner (Keuling et al.,
2009). Micro-RNA 193b expression is
suppressed in melanoma, and restora-
tion of its expression reduced melano-
ma proliferation in a non-apoptotic
manner through repression of CCND1
(Chen et al., 2010) andMCL1 expression,
www.jidonline.org 1771
MH Law et al.
Novel Pathways from Melanoma GWASs
again sensitizing these cells to ABT-737
(Chen et al., 2011).
INTERFERON AND MELANOMA?
Although little is known about the MX2
gene, found in the melanoma asso-
ciated 22q2.3 locus (Table 1), it is
expressed in response to the pro- and
anti-proliferation interferon-gamma
(IFNG) in an alveolar epithelial adeno-
carcinoma cell line (A459; Sanda et al.,
2006). Together with MX2, IFNG also
upregulates the expression of CASP8,
CLPTM1, and two genes in the 1q21.1
locus, MCL1 and CTSS (Sanda et al.,
2006). In mice, UVR-induced damage
to melanocytes leads to the recruitment
of IFNG-secreting macrophages, which
increased melanoma growth in an
IFNG-dependent manner (Zaidi et al.,
2011). It is intriguing to consider that
melanomagenesis may be influenced
by variants in genes identified by
GWAS by altering response to macro-
phage pro-tumorigenic properties.
CONCLUSIONS
Unlike many complex diseases and
cancers, a large proportion of melano-
ma risk arises from readily measurable
traits, which in the case of pigmentation
is itself under the control of a small
number of high-impact genes. These
traits are the exact endophenotypes so
desired of conditions less tractable to
genetic analysis such as schizophrenia,
and recognition of the utility of these
underlying phenotypes has provided
invaluable early insights into the genet-
ics of melanoma. Nevertheless, before
GWAS, candidate genes studies have
been plagued by poor replication and
ambiguous results, as recently reviewed
(Chatzinasiou et al., 2011). Only a few
genes have been reliably replicated,
and with the benefit of hindsight all
but the poorly graded vitamin D recep-
tor association have been indepen-
dently verified by these recent
GWASs, making the power and utility
of this method clear. Indeed, an advan-
tage of GWAS is the opportunity of
hypothesis-free identification of pre-
viously unconsidered pathways, as well
as a means to provide independent
replication of earlier results. The three
most recent melanoma GWASs have
thrown a spotlight on a greater role for
NER, BER, and cell cycle/senescence
mechanisms in melanoma. It is note-
worthy that many of the genes (or
pathways) recently shown to have
common variation associated with mel-
anoma are currently, or have the
potential to be, targets in cancer therapy
(PARP1, ATM, and the 1q42 genes,
including MCL1). Given the paucity of
treatments in melanoma, and the lack
of genetic variants associated with
cancer survival, these new genes should
bolster research in both areas.
The enrichment of intermediately
associated SNPs with P values between
1e-4 and 1e-6 (Barrett et al., 2011)
suggests that there is more to be
discovered with even larger sample
sets, which is in line with the hypoth-
esis that a substantial proportion of the
remaining heritable risk for melanoma
arises from common, low effect size
variants. Greater statistical power may
also be achieved through methodolo-
gies such as pathway analysis or gene-
based tests, which are currently being
applied to the melanoma sample sets
and will hopefully lead to a wave of
new findings.
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